Skip to main content
S 1276 115th Congress Senate Crime and Law Enforcement Alternative treatments Child health Drug therapy Drug trafficking and controlled substances Education programs funding Government studies and investigations Health personnel Health programs administration and funding Higher education Licensing and registrations Medical education Medical research Neurological disorders Research administration and funding Trade restrictions

Cannabidiol Research Expansion Act

Introduced: May 25, 2017 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 25, 2017
Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221)
May 25, 2017
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Cannabidiol Research Expansion Act

This bill requires the Drug Enforcement Administration (DEA) and the Department of Health and Human Services to each evaluate whether cannabidiol, the nonpsychoactive substance derived from marijuana or the synthetic formulation, should be a controlled substance under the Controlled Substances Act. After taking into consideration the evaluations, the DEA must initiate proceedings for classifying cannabidiol as a controlled substance if control is warranted.

The bill expands the authority for: (1) conducting medical research on cannabidiol and other nonpsychoactive components of marijuana, and (2) possessing or transporting cannabidiol or any other nonpsychoactive component of marijuana for certain medicinal purposes.

The Department of Justice shall register an applicant to manufacture or distribute cannabidiol or marijuana for the purpose of commercial production if approved by HHS.

Physicians who are licensed under state law may discuss the potential harms and benefits of cannabidiol or those components of marijuana as a treatment with their patients or the legal guardians of underage patients.

The bill terminates four years after enactment.

What's happening now May 25, 2017

Read twice and referred to the Committee on the Judiciary. (Sponsor introductory remarks on measure: CR S3220-3221)

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 7
All 7 Democratic 4 Republican 3
D
Klobuchar, Amy
Minnesota · Mar 19, 2018
 D
Kaine, Tim
Virginia · Nov 8, 2017
 D
Whitehouse, Sheldon
Rhode Island · Jul 11, 2017
 D
Durbin, Richard J.
Illinois · May 25, 2017
 R
Ernst, Joni
Iowa · May 25, 2017
 R
Grassley, Chuck
Iowa · May 25, 2017
 R
Tillis, Thomas
North Carolina · May 25, 2017
Cite this page click to expand
APA
U.S. Congress. (2026). S. 1276: Cannabidiol Research Expansion Act. 115th Congress. Open America. https://openamerica.io/bill/115-S-1276/
MLA
"S. 1276: Cannabidiol Research Expansion Act." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-S-1276/.
Bluebook (legal)
S. 1276, 115th Cong. (2026), https://openamerica.io/bill/115-S-1276/.
Markdown link
[S. 1276: Cannabidiol Research Expansion Act](https://openamerica.io/bill/115-S-1276/)
Report a problem